Saphris (asenapine maleate): Drug Safety Communication: Serious Allergic Reactions

Audience: Psychiatry, Patients [Posted 09/01/2011]

ISSUE: FDA notified healthcare professionals and patients that serious allergic reactions have been reported with the use of Saphris (asenapine maleate). The Contraindications, Warnings and…

Related posts:

1. Celexa (citalopram hydrobromide): Drug Safety Communication – Abnormal Heart Rhythms Associated With High Doses Audience: Psychiatry, Cardiology ISSUE: FDA notified healthcare professionals and patients...
2. Zyvox (linezolid): Drug Safety Communication – Serious CNS Reactions Possible When Given to Patients Taking Certain Psychiatric Medications Audience: Infectious Disease, Psychiatry, Family Practice ISSUE: FDA has received...
3. Methylene Blue: Drug Safety Communication – Serious CNS Reactions Possible When Given to Patients Taking Certain Psychiatric Medications Audience: Emergency Medicine, Critical Care Medicine, Psychiatry ISSUE: FDA has...
4. Multaq (dronedarone): Drug Safety Communication – Increased Risk of Death or Serious Cardiovascular Events Audience: Healthcare Professionals ISSUE: FDA notified healthcare professionals that it...
5. Valproate Products: Drug Safety Communication – Risk of Impaired Cognitive Development in Children Exposed In Utero (During Pregnancy) Audience: OBGYN, Neurology, Psychiatry Including valproate sodium (Depacon), divalproex sodium...